Medlink Medical Closes RMB 100 Million Series B Round

Zhejiang Medlink Medical Technology Co., Ltd. (hereinafter referred to as "Medlink Medical"), in order to accelerate the R&D iteration of its brain-computer interface (BCI) rehabilitation products, expand production capacity, and advance its nationwide market layout, has recently completed a RMB 100 million Series B round, jointly invested by Shanghai Chuangda Industry Control High-Tech Group Co., Ltd. and GSR United Capital.

Founded in 2018, Medlink Medical is a high-tech enterprise dedicated to the innovation and application of BCI technology in the medical rehabilitation field. The company is leading the construction of China's first provincial-level engineering research center in the BCI rehabilitation field. In 2024, the company's self-developed BCI rehabilitation training system was jointly selected by the Ministry of Industry and Information Technology and the National Health Commission and successfully included in the first batch of the High-End Medical Equipment Promotion and Application Program — and was also the only rehabilitation-sector project selected in this round of assessment. R&D personnel account for more than 50% of the company's workforce, with core members from well-known universities such as Zhejiang University.

As the first company in China to obtain a medical device registration certificate for BCI motor rehabilitation, Medlink Medical is deeply engaged in the non-implantable BCI rehabilitation field. It has obtained Class II medical device registration certificates for six models, with its products covering more than 20 devices. Medlink Medical's BCI-related rehabilitation equipment has been deployed at the Chinese PLA General Hospital, the Beijing Corps Hospital of the Chinese People's Armed Police Force, Wangjing Hospital, China Academy of Chinese Medical Sciences, Sir Run Run Shaw Hospital affiliated with Zhejiang University School of Medicine, Gem Flower Medical Group, and Zhengzhou University, among others. Its products have entered more than 150 hospitals nationwide, treated more than 100,000 patients in total, and reached a 40% share in public tendering in 2025, firmly securing its leadership in this niche segment.

The company has long focused on the application of non-invasive BCI in the precise diagnosis and treatment of emotional and affective disorders, brain disease rehabilitation, and long-term care. Through technical solutions and real-world application demonstrations, it aims to advance the innovation and implementation of brain health monitoring, closed-loop monitoring and intervention for emotional disorders, assisted brain disease rehabilitation, and long-term care services. According to statistics from the "China Stroke Prevention and Treatment Report," China has more than 28 million prevalent stroke patients, and about 75% of stroke survivors are left with varying degrees of motor, swallowing, and other functional impairments, often accompanied by comorbidities. Facing this severe prevention and treatment challenge, the company takes "motor + swallowing" as its breakthrough point to build an integrated non-invasive multifunctional BCI system covering diagnosis and treatment, rehabilitation, and long-term care, directly targeting four major bottlenecks: decoding accuracy, evidence-based validation, in-hospital and out-of-hospital continuity, and medical insurance reimbursement.

At the same time, through technological reserves in frontier BCI directions and interdisciplinary collaboration, the company is generating products such as a sleep and cognitive intervention ecosystem platform that integrates non-invasive BCI with generative AI, a rehabilitation system built on a brain–EMG fusion closed-loop neural interface for post-stroke dysphagia, and products for brain-controlled embodied intelligence, health monitoring, and early warning.

Dr. Cui Zhengzhe, founder of Medlink Medical, said, "This round of financing is an important milestone in the company's development. We will accelerate the building of a multimodal BCI neuromodulation large model, extend our products from hospitals to community and home rehabilitation settings, and enable BCI technology to benefit more patients."

A representative of the investors said that Medlink Medical has leading technological strength and a well-developed registration certificate system in the non-invasive BCI rehabilitation field, with deep clinical data accumulation, and that the investors are optimistic about its potential to lead the industry's development.

Zhejiang Medlink Medical Technology Co., Ltd. focuses on building the "Medlink Brain Control" brand, with human-machine integrated intelligent BCI at its core. Integrating R&D, production, and sales operations, it is committed to integrated research in the BCI rehabilitation field.

The EEG acquisition and rehabilitation training equipment independently developed, produced, and launched by the company has significant clinical value for the motor rehabilitation of patients with stroke and spinal cord injury. It has established a nationwide distributor network, with sales covering 15 provinces and having treated tens of thousands of patients, ranking first among companies in the same track. Zhejiang Medlink's equipment has served a cumulative total of 100,000+ patient visits and has won consistent praise from the hospitals where it is deployed.

While maintaining its first-mover advantage in the industry, Medlink Medical continues to invest in R&D. It has already obtained multiple products and Class II medical device registration certificates for numerous models of BCI rehabilitation products.

In terms of scientific research and innovation, the project has applied for 80 patents in total and has been granted 72 patents and software copyrights, including 13 granted invention patents, as well as 11 classes of registered trademarks. It has completed applications for two Zhejiang Provincial Key R&D Programs, with a total application amount of RMB 13 million, and the company, as a major participating unit, undertakes key work in research and industrialization.

In terms of corporate growth, Medlink Medical has been recognized as a national science and technology-based small and medium-sized enterprise, a Zhejiang provincial science and technology-based SME, an innovative SME, and a national high-tech enterprise, among others. In 2022, it led the formulation of a group standard. In 2023, it completed the certification of a Zhejiang Provincial Industrial New Product.

In October 2024, the "Zhejiang Engineering Research Center for Rehabilitation Medicine Brain-Computer Interface Technology and Equipment," led by Zhejiang Medlink Medical Technology Co., Ltd., was successfully approved. The center is China's first provincial- and ministerial-level scientific research platform in the BCI rehabilitation field. Bringing together innovative medical device enterprises, hospitals, universities, and research institutions, the center aims to integrate multidisciplinary, cross-professional industry-academia-research-medical resources in BCI technology, rehabilitation assessment and treatment, and the R&D and application of rehabilitation instruments and equipment; to carry out in-depth and comprehensive R&D of BCI rehabilitation technology; and to continuously provide complete sets of engineering and industrialization research results for the development of BCI rehabilitation technology. Rooted in Zhejiang and radiating across the country, it is of great significance to seizing the high ground of BCI innovation, responding to global health challenges, and addressing the numerous comorbid problems of an imminent aging society.

(This article is republished with authorization from "Zhejiang Medlink".)